Trials / Unknown
UnknownNCT04293276
Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer
Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (estimated)
- Sponsor
- Henan Cancer Hospital · Other Government
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study was to observe the efficacy and safety of treatment with pyrotinib and CDK4/6 inhibitor SHR6390 for HER2-positive metastatic breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pyrotinib | Pyrotinib Tablets |
| DRUG | SHR6390 | SHR6390 Tablets |
Timeline
- Start date
- 2020-04-01
- Primary completion
- 2021-08-23
- Completion
- 2023-05-01
- First posted
- 2020-03-03
- Last updated
- 2023-05-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04293276. Inclusion in this directory is not an endorsement.